Intravenous Bisphosphonate Therapy may Lead to Osteonecrosis of the Jaw in Multiple Myeloma, Breast, and Prostate Cancer Patients

References 

1. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369–376
   • Full Text
   • Full-Text PDF (119 KB)
   • CrossRef
2. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol. 2006;24:8S
3. Bamias A, Kastritis E, Bamia C, Moulopoulos L, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580–8587
   • MEDLINE
   • CrossRef
4. Dimopoulos M, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos L, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;9:968–971
5. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006 Feb;945–952
6. Woo S, Hellstein J, Kalmar J. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761